Toward Glioblastoma Treatment with High Spatiotemporal Precision: Controlling Temozolomide Release from Upconverting...

Area of Science:

• Biomedical Engineering
• Materials Science
• Oncology

Background:

• Temozolomide (TMZ) is a first-line glioblastoma (GBM) treatment but degrades rapidly in vivo.
• Effective drug delivery to GBM tumors is limited by premature degradation and severe side effects.
• Controlled drug release systems are needed to improve TMZ efficacy and patient outcomes.

Purpose of the Study:

• To develop a near-infrared (NIR) light-triggered drug delivery system for Temozolomide (TMZ).
• To protect TMZ from degradation and enable controlled release within glioblastoma multiforme (GBM) cells.
• To enhance the therapeutic efficacy of TMZ for GBM treatment.

Main Methods:

• Upconverting nanoparticles (UCNPs) were synthesized and coated with poly(acrylic acid) (PAA).
• TMZ was conjugated to the UCNP-PAA system via a UV-cleavable photolinker (PhL).
• NIR light was used to convert to UV light, triggering TMZ release from UCNPs within GBM cells.

Main Results:

• The UCNP@PAA-PhL-TMZ system demonstrated 100% TMZ release within 30 minutes under low-power NIR irradiation.
• NIR-triggered TMZ release after cellular internalization into U87MG GBM cells induced significant cell death.
• Lower TMZ concentrations with pulsed NIR release were effective, reducing potential side effects.

Conclusions:

• This NIR-controlled UCNP system effectively protects and releases TMZ, overcoming its degradation issues.
• On-demand drug release post-cellular internalization is crucial for enhanced chemotherapeutic efficacy.
• This technology offers a promising platform for personalized and effective GBM treatment strategies.